MOG and myeloid sarcoma: Despite high sensitivities and specificities of MOG antibody assays of 95-100% (10), testing MOG antibodies in patients with low probability of MOGAD, e.g. including all MS-caused ON and myelitis cases, leads to a significant occurrence of false-positive test results and is therefore not recommended (10, 15, 39).